Marianne Udd

Marianne Udd

Auto-generated profile, based on publicly available information

Marianne Udd

Gastrointestinal Surgery, Helsinki University Central Hospital, Helsinki, Finland

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 February 2007 in World Journal of Surgery
Verified
Journal Article
Closed access
PDF file
MUMarianne Udd
Marianne Udd
ALAri K. Leppäniemi
Ari K. Leppäniemi
SBSiamak Bidel
Siamak Bidel
PKPekka Keto
Pekka Keto
WRWolf‐Dieter Roth
Wolf‐Dieter Roth
RHReijo K. Haapiainen
Reijo K. Haapiainen

1 January 2001 in Scandinavian Journal of Gastroenterology
Verified
Journal Article
Closed access
MUM. Udd
M. Udd
PMP. Miettinen
P. Miettinen
APA. Palmu
A. Palmu
MHM. Heikkinen
M. Heikkinen
EJE. Janatuinen
E. Janatuinen
RJR. Julkunen
R. Julkunen
Background: It has been suggested that profound acid inhibition along with endoscopic therapy might prevent rebleeding and reduce mortality in patients with peptic ulcer bleeding. The aim of the study was to test the possible equivalence of a high dose and the regular dose of omeprazole in peptic ulcer bleeding. Methods: We performed a prospective randomized double-blind study involving 142 patients with acute peptic ulcer bleeding (Forrest classification I-II: spurting or oozing bleeding, non-bleeding visible vessel, clot and black base). One-hundred-and-two (71.8%) patients received endoscopic treatment (adrenaline injection and/or heater probe) in pre-entry. Patients were randomly assigned to receive the regular dose of omeprazole intravenously (20 mg once a day for 3 days, i.e. 60 mg/72 h) or a high dose of omeprazole (80 mg bolus + 8 mg/h for 3 days, i.e. 652 mg/72 h). Rebleeding, surgery and death were the outcome measures. Results: Six (8.2%) of the 73 patients receiving the regular dose of omeprazole and 8 (11.6%) of the 69 patients receiving the high dose of omeprazole rebled ( P = 0.002 for equivalence, equivalence limit 0.15). Three (4.1%) of the former patients and 5 (7.2%) of the latter group underwent surgery. Four (5.5%) patients in the regular-dose and 2 (2.9%) in the high-dose group died within 30 days. Conclusion: Under the defined tolerance limits, the regular dose of omeprazole is as successful as a high dose in preventing peptic ulcer rebleeding.

25 September 2017 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
MRMia Rainio
Mia Rainio
OLOuti Lindström
Outi Lindström
MUMarianne Udd
Marianne Udd
CHCarola Haapamäki
Carola Haapamäki
ANArno Nordin
Arno Nordin
LKLeena Kylänpää
Leena Kylänpää

5 June 2017 in Brain and Behavior
Verified
Journal Article
Open access
PDF file
MUMarianne Udd
Marianne Udd
JLJukka Lyytinen
Jukka Lyytinen
JEJohanna Eerola‐Rautio
Johanna Eerola‐Rautio
AKAnu Kenttämies
Anu Kenttämies
OLOuti Lindström
Outi Lindström
EPEero Pekkonen
Eero Pekkonen
Background: Continuous levodopa‐carbidopa intestinal gel (LCIG) diminishes daily “off” time and dyskinesia in patients with advanced Parkinson′s disease (PD). Complications are common with percutaneous endoscopic gastrostomy with a jejunal extension tube (PEG‐J).Aim of the Study: To report the clinical outcome of LCIG in patients with advanced PD in the years 2006–2014 at Helsinki University Hospital.Patients and Methods: Levodopa‐carbidopa intestinal gel treatment started following PEG‐J placement in patients with advanced PD after successful in‐hospital LCIG trial with a nasojejunal tube. Demographics, PEG‐J procedures, discontinuation of LCIG, complications and mortality were retrospectively analyzed.Results [mean (SD)]: Sixty patients with advanced PD [age 68(7) years; duration of PD: 11(4) years] had LCIG treatment for 26(23) months. The majority of patients with advanced PD were satisfied with the LCIG treatment. For 51 patients (85%), the pump was on for 16 hr a day, and for nine patients (15%) it was on for 24 hr a day. After 6 months, the levodopa‐equivalent daily dose (LEDD) had increased by 30% compared to pre‐LCIG LEDD. Sixty patients underwent a total of 156 PEG‐J procedures, and 48 patients (80%) had a total of 143 complications. Forty‐six patients (77%) had 119 PEG‐J or peristomal complications, and 22 patients (37%) had a total of 25 other complications. The most common complications were accidental removal of the J‐tube in 23 patients (38%) and ≥5% weight loss in 18 patients (30%). Fifteen patients discontinued the LCIG after 21 (21) months. At the end of the follow‐up period of 33(27) months, 38 patients were still on LCIG and nine (15%) had died.Conclusion: Most patients were satisfied with LCIG treatment. A few patients lost weight whereas the majority had complications with PEG‐J. When LCIG treatment is carried out, neurological and endoscopic units must be prepared for multiple endoscopic procedures.

1 January 2007 in Scandinavian Journal of Gastroenterology
Verified
Journal Article
Closed access
MUMarianne Udd
Marianne Udd
PMPekka Miettinen
Pekka Miettinen
APAntero Palmu
Antero Palmu
MHMarkku Heikkinen
Markku Heikkinen
EJEsko Janatuinen
Esko Janatuinen
RJRisto Julkunen
Risto Julkunen
Traditional non-steroidal anti-inflammatory drugs (NSAIDs) including ASA for thrombosis prophylaxis (ASA-TP), for pain medication (ASA-P) or non-ASA NSAIDs (NANSAIDs), Helicobacter pylori infection, CagA strains of H. pylori and smoking are reported risk factors for peptic ulcer bleeding (PUB), but the combined and the dose effects of these factors are controversial. The aim of this study was to estimate the significance of these risk factors and their combinations in PUB. PUB patients (n = 94) were compared with an age- (+/- 5 years) and gender-matched control group of non-ulcer patients (n = 94) attending elective endoscopy. A questionnaire on the possible risk factors (previous gastric and duodenal ulcer, use of ASA-TP, ASA-P, NANSAIDs, warfarin, alcohol and smoking) was completed. H. pylori infection was determined as positive if histology and/or urease tests were positive. CagA antibodies of IgG class were determined using an immunoblot method. H. pylori infection (odds ratio (OR) 8.8), the use of ASA-P (OR 3.5), ASA-TP (OR 4.07), NANSAIDs with > or =1 defined daily dose (OR 6.56), smoking > or =20 cigarettes daily (OR 6.43) and previous duodenal ulcer (DU) (OR 8.96) were independent risk factors for PUB. At least two risk factors were present in 65% of PUB patients. CagA strains were detected in 97% of the H. pylori-positive cases and in 96% of the respective controls. ASA, ibuprofen, ketoprofen and smoking were dose-dependent risk factors for PUB. Previous DU, H. pylori, the use of any ASA and smoking explained the majority of the PUB episodes. CagA strains of H. pylori were not associated with PUB. Two-thirds of the PUB patients had at least two risk factors, but their combination did not potentiate the risk.

26 January 2013 in Surgical Endoscopy
Verified
Journal Article
Closed access
PDF file
MMMax Mazanikov
Max Mazanikov
MUMarianne Udd
Marianne Udd
LKLeena Kylänpää
Leena Kylänpää
HMHarri Mustonen
Harri Mustonen
OLOuti Lindström
Outi Lindström
RPReino Pöyhiä
Reino Pöyhiä